Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18 USD | +1.81% | -9.90% | +64.72% |
05-10 | Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating | MT |
05-09 | Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+64.72% | 1.65B | |
+33.45% | 49.46B | |
+1.80% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.74% | 26.61B | |
-21.95% | 18.64B | |
+7.88% | 13.16B | |
+29.51% | 12.55B | |
+23.71% | 12.1B |
- Stock Market
- Equities
- EWTX Stock
- News Edgewise Therapeutics, Inc.
- Edgewise Says US FDA Grants Orphan Drug, Rare Pediatric Disease Designations for Investigational Muscular Dystrophy Therapy